CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Repertoire Genesis Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Repertoire Genesis Inc
No. 402
Saito Bioincubator, 7-7-15, Saito Asagi
Phone: +81 726578686p:+81 726578686 IBARAKI-SHI, OSK  567-0085  Japan Fax: +81 726578687f:+81 726578687
This company was Merged or Acquired on 5/31/2022.
This is a Subsidiary, click here for the Parent Company
Business Summary
Repertoire Genesis Inc is a Japan-based company mainly engaged in the business of supporting medical development (basic research, prevention, diagnosis, and treatment) that applies the immune system, mainly in the fields of cancer, autoimmune diseases, and infectious diseases. The Company defines two sales categories, research and development support and clinical development support, based on the differences in the way development support services are provided. Research and development support is a category that supports customers' basic research and development, and is a business area that provides relatively small-scale research support services mainly to academia, such as universities and public research institutions, mainly through sales agents. Clinical development support is a business area that supports customers' applied clinical development and promotes relatively large-scale and long-term development projects using clinical samples, mainly for pharmaceutical companies.
(Source: N-30D)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202112/31/2020Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Representative Director MasuoIchikawa
Founder RyujiSuzuki

General Information
Number of Employees: 16 (As of 12/31/2021)
Outstanding Shares: 3,114,000 (As of 12/31/2021)
Stock Exchange: TYO
Fax Number: +81 726578687


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 30, 2024